CO2020005885A2 - Derivados de piridinona y su uso como inhibidores selectivos de alk-2 - Google Patents
Derivados de piridinona y su uso como inhibidores selectivos de alk-2Info
- Publication number
- CO2020005885A2 CO2020005885A2 CONC2020/0005885A CO2020005885A CO2020005885A2 CO 2020005885 A2 CO2020005885 A2 CO 2020005885A2 CO 2020005885 A CO2020005885 A CO 2020005885A CO 2020005885 A2 CO2020005885 A2 CO 2020005885A2
- Authority
- CO
- Colombia
- Prior art keywords
- inhibitors
- pyridinone derivatives
- selective alk
- alk
- selective
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000005299 pyridinones Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La invención se refiere a un compuesto de Fórmula I o una de sus sales farmacéuticamente aceptables, un método para la fabricación de los compuestos de la invención, y sus usos terapéuticos. La presente invención además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2017/057389 WO2019102256A1 (en) | 2017-11-24 | 2017-11-24 | Pyridinone derivatives and their use as selective alk-2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020005885A2 true CO2020005885A2 (es) | 2020-07-31 |
Family
ID=60702886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0005885A CO2020005885A2 (es) | 2017-11-24 | 2020-05-14 | Derivados de piridinona y su uso como inhibidores selectivos de alk-2 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11160797B2 (es) |
| EP (1) | EP3713927B1 (es) |
| JP (1) | JP7091455B2 (es) |
| KR (1) | KR20200091422A (es) |
| CN (1) | CN111433195B (es) |
| AU (1) | AU2017440306B2 (es) |
| BR (1) | BR112020010171A2 (es) |
| CA (1) | CA3081651A1 (es) |
| CL (1) | CL2020001277A1 (es) |
| CO (1) | CO2020005885A2 (es) |
| CR (1) | CR20200211A (es) |
| CU (1) | CU20200035A7 (es) |
| DO (1) | DOP2020000088A (es) |
| EA (1) | EA202091293A1 (es) |
| EC (1) | ECSP20026023A (es) |
| ES (1) | ES2908252T3 (es) |
| IL (1) | IL274722A (es) |
| JO (1) | JOP20200127A1 (es) |
| MX (1) | MX2020005405A (es) |
| PE (1) | PE20201282A1 (es) |
| PH (1) | PH12020550763A1 (es) |
| RU (1) | RU2020120538A (es) |
| SG (1) | SG11202003920QA (es) |
| WO (1) | WO2019102256A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3117695A1 (en) | 2018-10-26 | 2020-04-30 | Keros Therapeutics, Inc. | Crystal forms of an alk2 inhibitor |
| WO2021222875A1 (en) * | 2020-04-30 | 2021-11-04 | Keros Therapeutics, Inc. | Methods of using alk2 inhibitors |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| CN113354631B (zh) * | 2021-06-01 | 2022-11-18 | 江苏大学 | 一种1,3,4-噁二唑衍生物及其制备方法和用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994011502A2 (en) | 1992-11-17 | 1994-05-26 | Ludwig Institute For Cancer Research | Activin receptor-like kinases, proteins having serine threonine kinase domains and their use |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US8895711B2 (en) | 2006-04-18 | 2014-11-25 | The Trustees Of The University Of Pennsylvania | Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP) |
| KR20090088852A (ko) | 2006-09-05 | 2009-08-20 | 메다렉스, 인코포레이티드 | 골형성 단백질의 항체와 이의 수용체 및 이의 사용방법 |
| EP2062048A4 (en) | 2006-09-12 | 2009-12-02 | Gen Hospital Corp | METHOD FOR IDENTIFYING CELL SIGNALING MODULATING COMPOUNDS AND METHOD FOR USING SUCH COMPOSITES |
| EP2265603B1 (en) | 2008-03-13 | 2014-05-07 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
| KR101862327B1 (ko) * | 2010-05-07 | 2018-05-29 | 질레드 코네티컷 인코포레이티드 | 피리돈 및 아자-피리돈 화합물 및 사용 방법 |
| WO2012023113A2 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Designer osteogenic proteins |
| KR20140014104A (ko) | 2010-12-06 | 2014-02-05 | 피라말 엔터프라이지즈 리미티드 | 치환된 이미다조퀴놀린 유도체 |
| HRP20180591T1 (hr) | 2012-03-01 | 2018-05-18 | Array Biopharma, Inc. | Inhibitori kinaze serina ili treonina |
| EP3122355A4 (en) * | 2014-03-26 | 2017-08-09 | The Brigham and Women's Hospital, Inc. | Compositions and methods for inhibiting bmp |
| JP2017536411A (ja) * | 2014-10-01 | 2017-12-07 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | Ｂｍｐ阻害用組成物及びｂｍｐ阻害方法 |
| CA2982664A1 (en) * | 2015-04-16 | 2016-10-20 | Merck Patent Gmbh | 3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one derivatives |
-
2017
- 2017-11-24 PE PE2020000516A patent/PE20201282A1/es unknown
- 2017-11-24 KR KR1020207017240A patent/KR20200091422A/ko not_active Ceased
- 2017-11-24 CR CR20200211A patent/CR20200211A/es unknown
- 2017-11-24 CA CA3081651A patent/CA3081651A1/en not_active Abandoned
- 2017-11-24 CN CN201780097129.0A patent/CN111433195B/zh active Active
- 2017-11-24 US US16/766,114 patent/US11160797B2/en active Active
- 2017-11-24 CU CU2020000035A patent/CU20200035A7/es unknown
- 2017-11-24 WO PCT/IB2017/057389 patent/WO2019102256A1/en not_active Ceased
- 2017-11-24 AU AU2017440306A patent/AU2017440306B2/en not_active Ceased
- 2017-11-24 EA EA202091293A patent/EA202091293A1/ru unknown
- 2017-11-24 SG SG11202003920QA patent/SG11202003920QA/en unknown
- 2017-11-24 EP EP17817144.3A patent/EP3713927B1/en active Active
- 2017-11-24 BR BR112020010171-0A patent/BR112020010171A2/pt not_active IP Right Cessation
- 2017-11-24 RU RU2020120538A patent/RU2020120538A/ru unknown
- 2017-11-24 MX MX2020005405A patent/MX2020005405A/es unknown
- 2017-11-24 JO JOP/2020/0127A patent/JOP20200127A1/ar unknown
- 2017-11-24 JP JP2020528328A patent/JP7091455B2/ja not_active Expired - Fee Related
- 2017-11-24 ES ES17817144T patent/ES2908252T3/es active Active
-
2020
- 2020-05-12 PH PH12020550763A patent/PH12020550763A1/en unknown
- 2020-05-13 EC ECSENADI202026023A patent/ECSP20026023A/es unknown
- 2020-05-14 CO CONC2020/0005885A patent/CO2020005885A2/es unknown
- 2020-05-14 DO DO2020000088A patent/DOP2020000088A/es unknown
- 2020-05-14 CL CL2020001277A patent/CL2020001277A1/es unknown
- 2020-05-17 IL IL274722A patent/IL274722A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020010171A2 (pt) | 2020-11-03 |
| AU2017440306A1 (en) | 2020-05-21 |
| WO2019102256A1 (en) | 2019-05-31 |
| US11160797B2 (en) | 2021-11-02 |
| RU2020120538A3 (es) | 2021-12-24 |
| JP7091455B2 (ja) | 2022-06-27 |
| IL274722A (en) | 2020-07-30 |
| PE20201282A1 (es) | 2020-11-24 |
| EP3713927A1 (en) | 2020-09-30 |
| KR20200091422A (ko) | 2020-07-30 |
| CN111433195A (zh) | 2020-07-17 |
| JP2021512850A (ja) | 2021-05-20 |
| CU20200035A7 (es) | 2021-03-11 |
| EP3713927B1 (en) | 2021-12-15 |
| SG11202003920QA (en) | 2020-06-29 |
| CA3081651A1 (en) | 2019-05-31 |
| CN111433195B (zh) | 2023-04-25 |
| JOP20200127A1 (ar) | 2020-05-21 |
| ECSP20026023A (es) | 2020-07-31 |
| RU2020120538A (ru) | 2021-12-24 |
| AU2017440306B2 (en) | 2021-01-28 |
| CL2020001277A1 (es) | 2020-11-13 |
| ES2908252T3 (es) | 2022-04-28 |
| CR20200211A (es) | 2020-06-19 |
| EA202091293A1 (ru) | 2020-11-23 |
| MX2020005405A (es) | 2020-08-13 |
| US20200360357A1 (en) | 2020-11-19 |
| DOP2020000088A (es) | 2020-08-31 |
| PH12020550763A1 (en) | 2021-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22047876A (es) | Derivados de pirazolilo ?tiles como agentes anticancer?genos | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| UY35663A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| UY33536A (es) | INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS | |
| MX389349B (es) | Derivados de ácido borónico y usos terapéuticos de los mismos. | |
| ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| CR20140032A (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como modulares de receptores de c5a | |
| CU20110207A7 (es) | Aril piridinas como inhibidoras de sintasa de aldosterona | |
| UY33075A (es) | Derivados de ciclohexano y usos de los mismos | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
| CL2020001277A1 (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk-2. | |
| EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| UY36123A (es) | Derivados de carboxamida | |
| UY33348A (es) | Compuestos de furopiridina y usos de los mismos | |
| MX2019003362A (es) | Compuestos de indazol para usar en lesiones de tendones y/o ligamentos. | |
| AR132461A2 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| CU20160170A7 (es) | Derivados de carboxamida | |
| UY35672A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos | |
| PY1446505A (es) | Compuestos derivados de piridilo biciclicos fusionados a anilo como inhibidores de fgfr4 | |
| PY1421755A (es) | Derivados de la pirazolopirrolidina y usi en el tratamiento de enfermedades |